60 related articles for article (PubMed ID: 38474177)
1. [Replication Machinery of Kaposi's Sarcoma-associated Herpesvirus and Drug Discovery Research].
Watanabe T; Fujimuro M
Yakugaku Zasshi; 2019; 139(1):69-73. PubMed ID: 30606932
[TBL] [Abstract][Full Text] [Related]
2. Pathological Features of Kaposi's Sarcoma-Associated Herpesvirus Infection.
Katano H
Adv Exp Med Biol; 2018; 1045():357-376. PubMed ID: 29896675
[TBL] [Abstract][Full Text] [Related]
3. Folate-Targeted Nanocarriers Co-Deliver Ganciclovir and miR-34a-5p for Combined Anti-KSHV Therapy.
Li F; Cao D; Gu W; Li D; Liu Z; Cui L
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474177
[TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of miR-34a-5p by phenylborate-coupled polyethylenimide nanocarriers for anti-KSHV treatment.
Li F; Cao D; Yao L; Gu W; Liu Z; Li D; Cui L
Front Bioeng Biotechnol; 2023; 11():1343956. PubMed ID: 38260739
[TBL] [Abstract][Full Text] [Related]
5. miR-34a-5p inhibits the malignant progression of KSHV-infected SH-SY5Y cells by targeting c-fos.
Wu S; Wu Z; Xu H; Zhang J; Gu W; Tan X; Pan Z; Cao D; Li D; Yang L; Li D; Pan Y
PeerJ; 2022; 10():e13233. PubMed ID: 35444864
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 Vpr Inhibits Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication by Inducing MicroRNA miR-942-5p and Activating NF-κB Signaling.
Yan Q; Shen C; Qin J; Li W; Hu M; Lu H; Qin D; Zhu J; Gao SJ; Lu C
J Virol; 2016 Oct; 90(19):8739-53. PubMed ID: 27440900
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic KSHV-encoded interferon regulatory factor upregulates HMGB2 and CMPK1 expression to promote cell invasion by disrupting a complex lncRNA-OIP5-AS1/miR-218-5p network.
Li W; Wang Q; Feng Q; Wang F; Yan Q; Gao SJ; Lu C
PLoS Pathog; 2019 Jan; 15(1):e1007578. PubMed ID: 30699189
[TBL] [Abstract][Full Text] [Related]
8. In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus.
Medveczky MM; Horvath E; Lund T; Medveczky PG
AIDS; 1997 Sep; 11(11):1327-32. PubMed ID: 9302441
[TBL] [Abstract][Full Text] [Related]
9. Enhanced Osteogenic Activity and Bone Repair Ability of PLGA/MBG Scaffolds Doped with ZIF-8 Nanoparticles Loaded with BMP-2.
Ma R; Su Y; Cao R; Wang K; Yang P
Int J Nanomedicine; 2023; 18():5055-5072. PubMed ID: 37701821
[TBL] [Abstract][Full Text] [Related]
10. An Overview of the Enhanced Effects of Curcumin and Chemotherapeutic Agents in Combined Cancer Treatments.
Cacciola NA; Cuciniello R; Petillo GD; Piccioni M; Filosa S; Crispi S
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628772
[TBL] [Abstract][Full Text] [Related]
11. Establishment and Evaluation of a Parametric Population Pharmacokinetic Model Repository for Ganciclovir and Valganciclovir.
Yang W; Mak W; Gwee A; Gu M; Wu Y; Shi Y; He Q; Xiang X; Han B; Zhu X
Pharmaceutics; 2023 Jun; 15(7):. PubMed ID: 37513988
[TBL] [Abstract][Full Text] [Related]
12. Targeted miR-34a delivery with PD1 displayed bacterial outer membrane vesicles-coated zeolitic imidazolate framework nanoparticles for enhanced tumor therapy.
Cui C; He Q; Wang J; Kang J; Ma W; Nian Y; Sun Z; Weng H
Int J Biol Macromol; 2023 Aug; 247():125692. PubMed ID: 37414322
[TBL] [Abstract][Full Text] [Related]
13. Biodegradable Imprinted Polymer Based on ZIF-8/DOX-HA for Synergistically Targeting Prostate Cancer Cells and Controlled Drug Release with Multiple Responses.
Song Y; Han S; Liu S; Sun R; Zhao L; Yan C
ACS Appl Mater Interfaces; 2023 May; 15(21):25339-25353. PubMed ID: 37212295
[TBL] [Abstract][Full Text] [Related]
14. Iron-based and BRD
Geng L; Lu T; Jing H; Zhou Y; Liang X; Li J; Li N
Acta Pharm Sin B; 2023 Feb; 13(2):863-878. PubMed ID: 36873167
[TBL] [Abstract][Full Text] [Related]
15. Optimizing ganciclovir and valganciclovir dosing regimens in pediatric patients with cytomegalovirus infection: a spotlight on therapeutic drug monitoring.
Li QY; van den Anker J; Wu YE; Hao GX; Zhao W
Expert Rev Clin Pharmacol; 2023; 16(8):727-739. PubMed ID: 36794592
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
